David Morris and Brian Chapin discuss practical management of metastatic hormone-sensitive prostate cancer. The conversation addresses key clinical dilemmas facing urologists and medical oncologists, ...

Zachary Klaassen hosts Luis Salgado to discuss metastasis-directed therapy for low-volume hormone-sensitive prostate cancer. The conversation highlights the challenge of interpreting disease volume in ...

Transurethral resection of the bladder tumor (TURBT) followed by intravesical Bacillus Calmette-Guérin (BCG) immunotherapy is a standard treatment for high-risk non muscle-invasive bladder cancer ...

artificial urinary sphincter outcomes, male incontinence device innovations, electronic artificial sphincter, adjustable male slings, new incontinence treatments, Comparison of Artificial Sphincter ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

Oliver Sartor is joined by Michael Hofman to discuss the VIOLET study evaluating Terbium-161 PSMA therapy in metastatic castration-resistant prostate cancer. Zachary Klaassen speaks with Oliver Sartor ...

Regional Variation in the Incidence and Prevalence of Peyronie's Disease in the United States-Results from an Encounters and Claims Database - Beyond the Abstract ...

High-Dose Chemotherapy as Initial Salvage Chemotherapy in Patients with Relapsed or Refractory Testicular Cancer: A Systematic Review and Meta-Analysis - Beyond the Abstract ...

The word “catheter” comes from Greek, meaning “to let or send down.” Catheters were used as early as 3,000 B.C. to relieve painful urinary retention. In those times, many materials were used to form a ...

Risk Model for Lymph Node-Positive Prostate Cancer After Radical Prostatectomy - Beyond the Abstract September 22, 2025 The Complex Interplay of Modifiable Risk Factors Affecting Prostate Cancer ...

Mark Tyson presents results from the BOND-003 study, evaluating the efficacy of cretostimogene grenadenorepvec monotherapy in treating BCG-unresponsive non-muscle-invasive bladder cancer.

At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Adam Kibel presents counterarguments to reclassifying Grade Group 1 prostate cancer as non-cancer ...